Coherus BioSciences to Report Fourth Quarter and Year End 2014 Financial Results on March 23

REDWOOD CITY, Calif., March 16, 2015 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), a late-stage clinical biologics platform company focused on the global biosimilar market, today announced that it has scheduled a conference call for Monday, March 23, 2015 at 1:30 p.m. PT / 4:30 p.m. ET to discuss its fourth quarter and year end 2014 financial results and product updates. Participating on the call will be Denny Lanfear, President and Chief Executive Officer, Barbara Finck, M.D., Chief Medical Officer, and Jean-Frederic Viret, Ph.D., Chief Financial Officer. Prepared remarks will be followed by a question and answer session.

Financial results will be released over the wire after market close on Monday, March 23, 2015 and posted at http://investors.coherus.com

Conference Call Information

When: March 23, 2015, 1:30 p.m. PT Dial-in: 844-452-6826 (domestic) or 765-507-2587 (international) Conference ID: 5132313 Webcast: http://investors.coherus.com Please join the conference call at least 10 minutes early to register. The webcast of the conference call will be available for replay through April 6, 2015.

About Coherus BioSciences, Inc.

Coherus is a leading pure-play, global biosimilar company with a focus on developing products for the major regulated markets. Composed of a team of industry veterans with decades of experience in bringing biologics to market, our goal is to become a worldwide leader in the biosimilar market by leveraging our biologics platform in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Coherus possesses late stage clinical products and commercialization partnerships with multinational pharmaceutical companies in Europe and Asia.

Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. For additional information, please visit www.coherus.com.

CONTACT: Susanna Chau
         Investor Relations
         Coherus BioSciences, Inc.
         [email protected]
         +1 (650) 649-3577

You May Also Be Interested In

• Growth isn't weak enough to truly undercut inflation pressures - BMO
• Netflix (NFLX) raised to Buy at Needham & Company on revenue upside
• Synovus Financial (SNV) PT Lowered to $42 at Piper Sandler